Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michal Canetti

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Emerging Infectious Diseases|April 26, 2024
SARS-CoV-2 IgG Levels as Predictors of XBB Variant Neutralization, Israel, 2022- and 2023Yaniv Lustig, Michal Canetti, Victoria Indenbaum, et al.
The New England Journal of Medicine|November 9, 2022
Six-Month Follow-up after a Fourth BNT162b2 Vaccine DoseMichal Canetti, Noam Barda, Mayan Gilboa, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|September 30, 2022
Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022Noam Barda, Michal Canetti, Mayan Gilboa, et al.
Nature Communications|March 23, 2023
Author Correction: Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-upMichal Canetti, Noam Barda, Mayan Gilboa, et al.
Nature Communications|December 13, 2022
Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-upMichal Canetti, Noam Barda, Mayan Gilboa, et al.
JAMA Network Open|May 23, 2023
Factors Associated With Protection From SARS-CoV-2 Omicron Variant Infection and Disease Among Vaccinated Health Care Workers in IsraelMayan Gilboa, Tal Gonen, Noam Barda, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 21, 2023
Corrigendum to "Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up" [Clin Microbiol Infect] 29 (7) (2023) 918-923Noam Barda, Yaniv Lustig, Victoria Indenbaum, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|March 15, 2023
Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-upNoam Barda, Yaniv Lustig, Victoria Indenbaum, et al.
Infectious Diseases and Therapy|May 24, 2025
Correction: West Nile Virus Outbreak in Israel 2024 Compared with Previous Seasons: A Retrospective StudyGuy Katzenellenbogen, Michal Canetti, Ili Margalit, et al.
Infectious Diseases and Therapy|April 3, 2025
West Nile Virus Outbreak in Israel 2024 Compared with Previous Seasons: A Retrospective StudyGuy Katzenellenbogen, Michal Canetti, Ili Margalit, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Emerging Infectious Diseases|April 26, 2024
SARS-CoV-2 IgG Levels as Predictors of XBB Variant Neutralization, Israel, 2022- and 2023Yaniv Lustig, Michal Canetti, Victoria Indenbaum, et al.
The New England Journal of Medicine|November 9, 2022
Six-Month Follow-up after a Fourth BNT162b2 Vaccine DoseMichal Canetti, Noam Barda, Mayan Gilboa, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|September 30, 2022
Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022Noam Barda, Michal Canetti, Mayan Gilboa, et al.
Nature Communications|March 23, 2023
Author Correction: Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-upMichal Canetti, Noam Barda, Mayan Gilboa, et al.
Nature Communications|December 13, 2022
Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-upMichal Canetti, Noam Barda, Mayan Gilboa, et al.
JAMA Network Open|May 23, 2023
Factors Associated With Protection From SARS-CoV-2 Omicron Variant Infection and Disease Among Vaccinated Health Care Workers in IsraelMayan Gilboa, Tal Gonen, Noam Barda, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 21, 2023
Corrigendum to "Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up" [Clin Microbiol Infect] 29 (7) (2023) 918-923Noam Barda, Yaniv Lustig, Victoria Indenbaum, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|March 15, 2023
Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-upNoam Barda, Yaniv Lustig, Victoria Indenbaum, et al.
Infectious Diseases and Therapy|May 24, 2025
Correction: West Nile Virus Outbreak in Israel 2024 Compared with Previous Seasons: A Retrospective StudyGuy Katzenellenbogen, Michal Canetti, Ili Margalit, et al.
Infectious Diseases and Therapy|April 3, 2025
West Nile Virus Outbreak in Israel 2024 Compared with Previous Seasons: A Retrospective StudyGuy Katzenellenbogen, Michal Canetti, Ili Margalit, et al.
Pageof 3